Switch to:
More From Other Websites
8:02 am Cubist Pharma: Merck (MRK) begins tender offer to acquire... Dec 21 2014
[$$] FDA Approves Cubist's Experimental Antibiotic Zerbaxa Dec 19 2014
FDA Approves Second Cubist Antibiotic Of 2014 Dec 19 2014
Cubist Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated... Dec 19 2014
Cubist Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated... Dec 19 2014
FDA approves Cubists' drug for antibiotic-resistant bacteria Dec 19 2014
CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Temporary Suspension of Trading Under Registrant's... Dec 19 2014
Merck Begins Tender Offer to Acquire Cubist Dec 19 2014
$100 trillion Superbugs threat Dec 18 2014
Tetraphase Jumps As 'Superbug' Drug Scores In Trial Dec 18 2014
Cubist Pharma downgraded by UBS Dec 17 2014
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Cubist... Dec 15 2014
Charting the Market Dec 13 2014
SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Cubist... Dec 12 2014
CBST SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches Investigation of the Board of... Dec 12 2014
CUBIST PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of... Dec 11 2014
Lifshitz & Miller Law Firm Announces Investigation of Actuate Corporation, Albany Molecular Research... Dec 11 2014
Goldman deals pass $1 trillion for 2014 Dec 11 2014
Merck-Cubist Deal On Despite Patent Setback, Shares Fall Dec 10 2014
CBST SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation of the Board of Directors of... Dec 10 2014


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK